ImmuneBridge
San Francisco
About ImmuneBridge
ImmuneBridge is developing allogeneic immunotherapies for cancer. ImmuneBridge's key innovation fosters the development of immune stem cells obtained from cord blood and creates a fresh, adaptable, reliable, and plentiful cellular source for immunotherapies. They are currently looking for natural killer cell-based treatments for hematological cancers. They will then attack solid tumors using the special benefits of their cellular source.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $25.3M
- Funding stage: Seed
- Last round: Seed (Mar 2026)
- Website: immunebridge.com
- Phone: 415-624-6411
Industries & Categories
Biotechnology, Health Care, Information Technology
Social Profiles
Canonical: https://fsome.com/organization/immunebridge-6662 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.